Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Ahead of the big pharma's earnings call July 29, Sanofi-Aventis is under renewed pressure with Momenta and partner Sandoz promising a swift launch of their newly approved generic version of Lovenox.

You may also be interested in...



Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely

Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition

Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely

Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition

Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely

Sanofi-Aventis is interested in acquiring a company with market cap up to $20 billion, CEO Viehbacher says, leaving open the possibility of acquiring Genzyme.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel